McKesson (MCK) Reports Q4 Earnings: What Key Metrics Have to Say

For the quarter ended March 2024, McKesson (MCK) reported revenue of $76.36 billion, up 10.8% over the same period last year. EPS came in at $6.18, compared to $7.19 in the year-ago quarter.

The reported revenue represents a surprise of -3.00% over the Zacks Consensus Estimate of $78.72 billion. With the consensus EPS estimate being $6.34, the EPS surprise was -2.52%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- U.S. Pharmaceutical: $68.79 billion compared to the $71.06 billion average estimate based on four analysts. The reported number represents a change of +11.5% year over year.
  • Revenue- Prescription Technology Solutions: $1.18 billion versus $1.26 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.2% change.
  • Revenue- International: $3.55 billion versus $3.39 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.
  • Revenue- Medical-Surgical Solutions: $2.84 billion versus the four-analyst average estimate of $2.78 billion. The reported number represents a year-over-year change of +5.5%.
  • Adjusted Operating Profit- U.S. Pharmaceutical: $901 million versus the four-analyst average estimate of $919.98 million.
  • Adjusted Operating Profit- International: $94 million versus $93.30 million estimated by four analysts on average.
  • Adjusted Operating Profit- Corporate: -$193 million versus -$176.82 million estimated by four analysts on average.
  • Adjusted Operating Profit- Prescription Technology Solutions: $212 million versus $235.16 million estimated by four analysts on average.
  • Adjusted Operating Profit- Medical-Surgical Solutions: $248 million versus $232.82 million estimated by four analysts on average.
View all Key Company Metrics for McKesson here>>>

Shares of McKesson have returned +0.2% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Where Will Stocks Go…

If Biden Wins? If Trump Wins?

The answers may surprise you.

Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!

Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…

1. Medical manufacturer has gained +11,000% in the last 15 years.

2. Rental company is absolutely crushing its sector.

3. Energy powerhouse plans to grow its already large dividend by 25%.

4. Aerospace and defense standout just landed a potentially $80 billion contract.

5. Giant Chipmaker is building huge plants in the U.S. 

Hurry, Download Special Report FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

McKesson Corporation (MCK) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.